{
    "elements": [
        {
            "type": "image",
            "sequence_num": 1,
            "data": {
                "url": "11063 Neuropathic pain 4.0.001.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 2,
            "data": {
                "num_rows": 15,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Document Title:"
                    },
                    {
                        "text": "NEUROPATHIC PAIN \u2013 GENERAL GUIDELINES AND ESSENTIAL INFORMATION"
                    },
                    {
                        "text": "Document Reference/Register no:"
                    },
                    {
                        "text": "11063"
                    },
                    {
                        "text": "Version Number:"
                    },
                    {
                        "text": "4.0"
                    },
                    {
                        "text": "Document type: (Policy/ Guideline/ SOP/CCP)"
                    },
                    {
                        "text": "Clinical Guideline"
                    },
                    {
                        "text": "To be followed by: (Target Staff)"
                    },
                    {
                        "text": "All qualified nursing and medical staff"
                    },
                    {
                        "text": "Ratification Issue Date: (Date document is uploaded onto the intranet)"
                    },
                    {
                        "text": "04 May 2021"
                    },
                    {
                        "text": "Review Date:"
                    },
                    {
                        "text": "03 May 2024"
                    },
                    {
                        "text": "Developed in response to:"
                    },
                    {
                        "text": "NICE guidelines for neuropathic pain in adults"
                    },
                    {
                        "text": "Contributes to HSC Act 2008 (Regulated Activities) Regulations 2014(Part 3); and CQC Regulations 2009 (Part 4) CQC Fundamental Standards of Quality and Safety:"
                    },
                    {
                        "text": "12"
                    },
                    {
                        "text": "Issuing Division/Directorate:"
                    },
                    {
                        "text": "Integrated Pain Management Service"
                    },
                    {
                        "text": "Author/Contact: (Asset Administrator)"
                    },
                    {
                        "text": "Claudine Riordan, Pain CNS"
                    },
                    {
                        "text": "Hospital Sites: (tick appropriate box/es to indicate status of policy review i.e. joint/ independent)"
                    },
                    {
                        "text": "\u2610 MSE NHS Foundation Trust \u2610 Basildon Hospital \u2612 Broomfield Hospital \u2610 Southend Hospital \u2610 Other (please state)"
                    },
                    {
                        "text": "Consultation:"
                    },
                    {
                        "text": "Refer to pages 1 & 2"
                    },
                    {
                        "text": "Approval Group / Committee(s):"
                    },
                    {
                        "text": "Pain Service Group: Clinical Lead, Nurse Consultant, Senior CNS"
                    },
                    {
                        "text": "16 April 2021"
                    },
                    {
                        "text": "Professionally Approved by: (Asset Owner)"
                    },
                    {
                        "text": "Dr Tom Durcan, Lead for Inpatient Pain"
                    },
                    {
                        "text": "16 April 2021"
                    },
                    {
                        "text": "Ratification Group(s):"
                    },
                    {
                        "text": "Joint Document Management Group"
                    },
                    {
                        "text": "04 May 2021"
                    },
                    {
                        "text": "Executive and Clinical Directors (Communication of minutes from Document Ratification Group)"
                    },
                    {
                        "text": "May 2021"
                    },
                    {
                        "text": "Distribution Method:"
                    },
                    {
                        "text": "\u2612Trust Intranet"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "image",
            "sequence_num": 3,
            "data": {
                "url": "11063 Neuropathic pain 4.0.002.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 4,
            "data": {
                "num_rows": 4,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Consulted With: this must include Pharmacy if the document has any reference to medication"
                    },
                    {
                        "text": "Post/ Approval Committee/ Group:"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "Dr Carol McCartney, Dr Victor Mendis, Dr Mark Alexander-Williams, Dr Tom Durcan, Dr Subodha Thanthulage"
                    },
                    {
                        "text": "Pain Consultants"
                    },
                    {
                        "text": "15 April 2021"
                    },
                    {
                        "text": "Lynne Mustard"
                    },
                    {
                        "text": "Service Manager, Pain Department"
                    },
                    {
                        "text": "15 April 2021"
                    },
                    {
                        "text": "Alison Bloor"
                    },
                    {
                        "text": "Pain Specialist Pharmacist"
                    },
                    {
                        "text": "15 April 2021"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 5,
            "data": {
                "num_rows": 2,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Related Trust Policies (to be read in conjunction with)"
                    },
                    {
                        "text": "Policy for the Use of Medicines"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 6,
            "data": {
                "num_rows": 7,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Review History:"
                    },
                    {
                        "text": "Version No:"
                    },
                    {
                        "text": "Authored/Reviewer:"
                    },
                    {
                        "text": "Summary of amendments/ Record documents superseded by:"
                    },
                    {
                        "text": "Issue Date:"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Author's Name"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Jayne Somerset"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "23 October 2014"
                    },
                    {
                        "text": "2.0"
                    },
                    {
                        "text": "Jayne Somerset"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "24 November 2014"
                    },
                    {
                        "text": "3.0"
                    },
                    {
                        "text": "Jayne Somerset"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "20 March 2018"
                    },
                    {
                        "text": "4.0"
                    },
                    {
                        "text": "Claudine Riordan"
                    },
                    {
                        "text": "Full review; transfer to MSE template"
                    },
                    {
                        "text": "04 May 2021"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 7,
            "data": {
                "is_heading": 1,
                "text": "Contents"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 8,
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "Introduction ..................................................................................................................."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 9,
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "Scope ............................................................................................................................. 3 Table of Definitions"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 10,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Roles & Responsibilities within the Trust ..................................................................."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 11,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "Background ..................................................................................................................."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 12,
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "Definition of Neuropathic Pain ....................................................................................."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 13,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "Aetiology........................................................................................................................"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 14,
            "data": {
                "is_heading": 1,
                "prefix": 8.0,
                "text": "Clinical Presentation ...................................................................................................."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 15,
            "data": {
                "is_heading": 1,
                "prefix": 9.0,
                "text": "Treatment....................................................................................................................... 10 Identifying and Treating Underlying Causes\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 \u2026\u2026 11 Making a Pharmacological Plan\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 12 When to refer to the Specialist Pain Service\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026. 13 Summary of Drug Groups\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.. 14 Algorithm for Pharmacological Neuropathic Pain Care Guidelines\u2026\u2026\u2026\u2026\u2026... 15 Infection Control\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026... 16 Non- Compliance with this Guideline\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026. 17 Staff & Training ............................................................................................................. 18 Audit and Monitoring\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.. 19 Approval and Implementation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 16,
            "data": {
                "is_heading": 1,
                "text": "20 Equality and Diversity .................................................................................................. 21 References\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 17,
            "data": {
                "is_heading": 1,
                "prefix": 22.0,
                "text": "Further Information\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 18,
            "data": {
                "is_heading": 1,
                "prefix": 96.0,
                "text": "Appendix 1: Licensed indications for recommended pharmacological treatments for neuropathic pain (March 2010) Nice guidelines  ....................................................."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 19,
            "data": {
                "is_heading": 1,
                "text": "Appendix 2: Examples of neuropathic pain syndromes ................................................... Appendix 3: DN-4 Neuropathic Pain Questionnaire\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026. Appendix 4: Glossary of Pain Terminology\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 20,
            "data": {
                "is_heading": 1,
                "text": "Appendix 5: Pharmacological treatments considered for the clinical guideline on neuropathic pain\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 21,
            "data": {
                "is_heading": 1,
                "text": "Appendix 6 Neuopathic Pain Care Flowchart\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 Appendix 7 Drugs Table"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 22,
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "Introduction"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 23,
            "data": {
                "is_heading": 0,
                "prefix": 18.0,
                "text": "It is intended to assist medical staff to assess, diagnose, and formulate a pharmacological treatment plan for patients over  years old who have neuropathic pain in non-specialist settings. Non-specialist settings include hospital care. It also includes recommendations to when referral to a Specialist Pain service can be made."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 24,
            "data": {
                "is_heading": 1,
                "prefix": 1.2,
                "text": "The neuropathic guidelines are set out to treat neuropathic pain as a \u2018blanket condition'. However, from the evidence it is clear that there are various subpopulations where treatment does differ. For example diabetic neuropathy, post herpetic neuralgia, Trigeminal neuralgia and Complex Regional Pain Syndrome (CRPS). Please refer to the Integrated Pain Management Service (IPMS) for advice regarding these conditions."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 25,
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "Scope"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 26,
            "data": {
                "is_heading": 0,
                "prefix": 2.1,
                "text": "This guideline is for qualified medical staff working in non-specialist settings treating patients 18 years and over with neuropathic pain. Non-specialist settings include hospital care. The guideline excludes acute neuropathic pain arising directly from trauma or orthopaedic surgical procedures. It also does not include patients who are being treated in specialist pain services."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 27,
            "data": {
                "is_heading": 0,
                "prefix": 2.2,
                "text": "The guidelines are recommendations regarding the treatment and care of people with neuropathic pain. They have been derived from careful consideration of evidence available at the time. Implementation of this guideline does not override the responsibility of the doctor who diagnoses and prescribes for this type of pain, and should be used in conjunction with clinical judgement."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 28,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Definitions"
            }
        },
        {
            "type": "table",
            "sequence_num": 29,
            "data": {
                "num_rows": 5,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Abbreviation"
                    },
                    {
                        "text": "Definition"
                    },
                    {
                        "text": "NeuPSIG"
                    },
                    {
                        "text": "Neuropathic Pain Specialist Group"
                    },
                    {
                        "text": "NP"
                    },
                    {
                        "text": "Neuropathic pain"
                    },
                    {
                        "text": "CRPS"
                    },
                    {
                        "text": "Complex regional pain syndrome"
                    },
                    {
                        "text": "CNS"
                    },
                    {
                        "text": "Central nervous system"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 30,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Roles and responsibilities within the Trust"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 31,
            "data": {
                "is_heading": 0,
                "prefix": 4.1,
                "text": "The prescribing doctor remains responsible for the diagnosis, and prescribing of medication and the on-going monitoring of their patient."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 32,
            "data": {
                "is_heading": 0,
                "prefix": 4.2,
                "text": "For the prescribing doctor it is the individual's responsibility to identify training needs and seek appropriate help, either from the IPMS or their senior colleagues."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 33,
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "The guideline assumes that the prescriber will use the particular drugs summary of product characteristics (SPC) and the British National Formulary (BNF) prior to prescribing. This information will provide special warnings, precautions for use, contraindications and adverse effects of the drug. Some of the drugs suggested are outside their licensed indication; however there is good evidence to suggest they are effective for the purpose of treating Neuropathic pain. Please see Appendix ."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 34,
            "data": {
                "is_heading": 0,
                "prefix": 4.4,
                "text": "Referral to a Specialist Pain Service does not mean an exit from non-specialist care by the prescriber but should be viewed as the start to a collaborative ongoing approach to the management of the patient's neuropathic pain."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 35,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "Background"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 36,
            "data": {
                "is_heading": 0,
                "prefix": 5.1,
                "text": "Several advances have been made in the last few decades regarding neuropathic pain. Neuropathic pain develops as a result of damage to, or dysfunction of, the system that normally signals pain. The damage / dysfunction occur within the peripheral or central nervous system, leaving the damaged peripheral or central nerves to respond differently. There can be a huge variation in patient response to this change i.e. their symptoms, and their underlying aetiology. Every patient is different."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 37,
            "data": {
                "is_heading": 0,
                "prefix": 5.2,
                "text": "Due to this large variation there is no standardised set of accepted tests that may be applied to every patient when diagnosing neuropathic pain. The availability of neuropathic pain screening tools may help (such as pain DETECT, the LANSS pain scale, DN4, ID-P AIN, Neuropathic Pain Questionaire, etc, sensory testing, skin biopsies), however making a diagnosis is still based on patient verbal descriptors of their pain, clinical examination and judgment."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 38,
            "data": {
                "is_heading": 0,
                "prefix": 5.3,
                "text": "In addition to this information there are numerous pharmacological treatments available. There seems to be huge variability to how neuropathic pain once assessed, how treatment is initiated, whether the therapeutic doses are achieved, and whether there is a correct sequencing of therapeutic drug classes."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 39,
            "data": {
                "is_heading": 0,
                "prefix": 5.4,
                "text": "The NICE guidelines have been made to assist the practitioner step by step what to prescribe these patients. Traditional analgesics will have very little effect on this type of pain, however may help with any nociceptive crossover pain the patient may have. Our guidelines have been set out to mirror the NICE guidelines. They are the most up to date evidenced based help available in the Trust."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 40,
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "Definition of neuropathic pain"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 41,
            "data": {
                "is_heading": 0,
                "prefix": 6.1,
                "text": "The definition of neuropathic pain has recently been revised by an expert committee of the Neuropathic Pain Special Interest Group of the International Association for the Study of Pain (NeuPSIG) as \"pain arising as direct consequence of a lesion or disease affecting the somatosensory system\u201d. It differs from inflammatory or nociceptive pain, which is caused by actual tissue damage or potentially tissue damaging stimuli. Neuropathic pain (NP) is produced either by damage to, or pathological change in, the peripheral or central nervous system, the system that normally signals pain."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 42,
            "data": {
                "is_heading": 1,
                "prefix": 6.2,
                "text": "What is required to treat neuropathic pain are analgesics which directly have an effect on the dysfunctional nerves, this is why the analgesics used to treat NP are so different from those to treat nociceptive / inflammatory pain. Traditional analgesics i.e. opioids, NSAIDs have little effect on reducing NP."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 43,
            "data": {
                "is_heading": 0,
                "prefix": 6.3,
                "text": "Damage to the somatosensory system can provoke a range of responses. This accounts for the variation in patient symptoms on clinical presentation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 44,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "Aetiology"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 45,
            "data": {
                "is_heading": 0,
                "prefix": 7.1,
                "text": "Neuropathic pain can be caused by several different disease processes, which can often overlap. Currently there is no universally accepted classification for the disorder. There are however, four broad classes of diseases accepted based on aetiology and anatomythat can elicit neuropathic pain. These include:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 46,
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "For examples of neuropathic pain syndromes see Appendix ."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 47,
            "data": {
                "is_heading": 1,
                "prefix": 8.0,
                "text": "Clinical presentation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 48,
            "data": {
                "is_heading": 0,
                "prefix": 8.1,
                "text": "There is no finite standardised diagnostic procedure for neuropathic pain. Screening methods such as questionnaires mentioned fail to identify 10-20% of patients with neuropathic pain. The DN-4 Neuropathic Questionnaire has been included in the Appendix 3 if required. They can be useful but they are not a substitute for clinical judgment."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 49,
            "data": {
                "is_heading": 0,
                "prefix": 8.2,
                "text": "Believe the patient. Record their descriptors accurately. Try not to coerce the patient by offering descriptors of neuropathic pain. Let them describe pain / sensations to you."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 50,
            "data": {
                "is_heading": 0,
                "prefix": 8.3,
                "text": "Assess the patients' pain by establishing the onset, location, quality, intensity, and duration of the pain."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 51,
            "data": {
                "is_heading": 1,
                "prefix": 8.4,
                "text": "Neuropathic types of pain have irrespective of underlying aetiology certain essential characteristics."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 52,
            "data": {
                "is_heading": 0,
                "text": "Sensory deficit in the painful area;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 53,
            "data": {
                "is_heading": 0,
                "text": "Allodynia or hyperalgesia in the painful area;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 54,
            "data": {
                "is_heading": 0,
                "text": "Aftersensations;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 55,
            "data": {
                "is_heading": 0,
                "text": "Gradual increase of pain following repetitive stimulation;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 56,
            "data": {
                "is_heading": 0,
                "text": "Paroxysms of pain;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 57,
            "data": {
                "is_heading": 0,
                "text": "In particular two paradoxical clinical features: loss of sensation and increased sensation are met by most neuropathic pain conditions and reflect; deafferentation or lost input to the CNS (central nervous system) together with the presence of neuronal hyperexcitability."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 58,
            "data": {
                "is_heading": 0,
                "prefix": 8.5,
                "text": "Inability to distinguish warm from cold objects suggests an altered thermal threshold. Patients may complain that the painful area is abnormally sensitive to any innocuous mechanical or thermal stimulus; sometimes clothes brushing against the area or a cold draught of air can be intensely painful."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 59,
            "data": {
                "is_heading": 0,
                "prefix": 8.6,
                "text": "Features of neuropathic pain may be evident within days of nerve damage or can take months to develop. Sometimes, a minor insult to an area of previous injury that had healed without problem can trigger neuropathic pain. Severity of the pain often does not correspond with the seriousness of the underlying condition. For example, post herpetic neuralgia (pain after shingles) can cause a severe pain, even though there is no rash or sign of infection remaining."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 60,
            "data": {
                "is_heading": 0,
                "prefix": 8.7,
                "text": "Concomitant conditions may be present in patients with chronic neuropathic pain. These include anxiety, sleep disturbance and depression."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 61,
            "data": {
                "is_heading": 0,
                "prefix": 4.0,
                "text": "Below is a summary of symptoms that can be experienced by the patient. A glossary of the above terms can be found in the Appendix  Spontaneous Pain can be described as burning, throbbing, stabbing, shooting. Abnormal sensations may include itching, numbness, tingling, pricking, pins and needles sensations, crawling."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 62,
            "data": {
                "is_heading": 1,
                "text": "Symptoms of Neuropathic Pain can be classified into"
            }
        },
        {
            "type": "image",
            "sequence_num": 63,
            "data": {
                "url": "11063 Neuropathic pain 4.0.003.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 64,
            "data": {
                "is_heading": 0,
                "text": "Neuropathic pain \u2013 general guidelines and essential information/11063/4.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 65,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 66,
            "data": {
                "is_heading": 1,
                "text": "Spontaneous Pain"
            }
        },
        {
            "type": "image",
            "sequence_num": 67,
            "data": {
                "url": "11063 Neuropathic pain 4.0.007.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 68,
            "data": {
                "is_heading": 0,
                "text": "intermittent,"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 69,
            "data": {
                "is_heading": 0,
                "text": "paroxysmal"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 70,
            "data": {
                "is_heading": 1,
                "text": "Stimulus-evoked Pain"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 71,
            "data": {
                "is_heading": 1,
                "text": "Abnormal sensations"
            }
        },
        {
            "type": "image",
            "sequence_num": 72,
            "data": {
                "url": "11063 Neuropathic pain 4.0.010.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 73,
            "data": {
                "is_heading": 0,
                "text": "Allodynia"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 74,
            "data": {
                "is_heading": 0,
                "text": "Hyperalgesia"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 75,
            "data": {
                "is_heading": 1,
                "text": "Hyperaesthesia  \uf0b7\uf0b7  PDysetarathheessiiaass"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 76,
            "data": {
                "is_heading": 0,
                "text": "Hyperpathia"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 77,
            "data": {
                "is_heading": 0,
                "text": "Hypoaesthesia"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 78,
            "data": {
                "is_heading": 0,
                "text": "Hypoalgesia"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 79,
            "data": {
                "is_heading": 0,
                "prefix": 8.9,
                "text": "Demonstration of these painful symptoms and / or altered sensations, along"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 80,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "with a history that may match a neuroanatomical or dermatomal pattern would be enough to form a probable diagnosis of neuropathic pain. DN-4 questionnaire may also be used to reinforce clinical findings. See Appendix ."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 81,
            "data": {
                "is_heading": 1,
                "prefix": 9.0,
                "text": "Treatment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 82,
            "data": {
                "is_heading": 0,
                "text": "Includes:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 83,
            "data": {
                "is_heading": 0,
                "text": "Treating the underlying cause"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 84,
            "data": {
                "is_heading": 0,
                "text": "Pharmacological based treatments"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 85,
            "data": {
                "is_heading": 0,
                "text": "Psychological treatment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 86,
            "data": {
                "is_heading": 0,
                "text": "Referral to Specialist Pain Services"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 87,
            "data": {
                "is_heading": 1,
                "prefix": 10.0,
                "text": "Identify and treating the underlying cause"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 88,
            "data": {
                "is_heading": 0,
                "prefix": 10.1,
                "text": "If possible, it may help to ease the pain. For example, good control of diabetes will ease the pain in a metabolic induced neuropathic pain. Nerve decompression will reduce the pain where a nerve is trapped. Removal of by surgery or shrinkage of by radiotherapy of a tumour may ease the pain where pressure on the surroundings nerves maybe the cause."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 89,
            "data": {
                "is_heading": 0,
                "prefix": 10.2,
                "text": "Ruling out systemic disease:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 90,
            "data": {
                "is_heading": 0,
                "text": "Review of systems through laboratory bloods and serologic tests;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 91,
            "data": {
                "is_heading": 0,
                "text": "Alcohol intake;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 92,
            "data": {
                "is_heading": 0,
                "text": "Family history;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 93,
            "data": {
                "is_heading": 0,
                "text": "HIV Status."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 94,
            "data": {
                "is_heading": 1,
                "prefix": 11.0,
                "text": "Making a pharmacological plan"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 95,
            "data": {
                "is_heading": 0,
                "prefix": 11.1,
                "text": "A variety of pharmacological treatments exist. In general, start with monotherapy, but consider combination therapy early on. Combination therapy with drugs that result in additive or synergistic effects to target different pain mechanisms is a logical approach because less than half of all patients will achieve a significant benefit with any single medical treatment for neuropathic pain. The evidence, however, to support the idea that combination therapy is likely to be more efficacious and safer than each drug alone is less developed than that for single drugs."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 96,
            "data": {
                "is_heading": 1,
                "prefix": 11.2,
                "text": "Please read the appropriate sequencing of anti-neuropathic pain drugs (refer to appendix 6). Therapeutic doses need to be achieved; unless side effects are intolerable for the patient. Allow for a trial period."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 97,
            "data": {
                "is_heading": 0,
                "prefix": 11.3,
                "text": "When agreeing a plan, discuss the following with the patient:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 98,
            "data": {
                "is_heading": 0,
                "text": "The severity of their pain, and its impact on their lifestyle, setting realistic expectations and outcomes of any intervention / treatment being offered;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 99,
            "data": {
                "is_heading": 0,
                "text": "Benefits and possible adverse effects of treatment;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 100,
            "data": {
                "is_heading": 0,
                "text": "Why a particular treatment is being offered;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 101,
            "data": {
                "is_heading": 0,
                "text": "The importance of dose titration and the titration process, providing the patient with information and advice;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 102,
            "data": {
                "is_heading": 0,
                "text": "Additional coping strategies;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 103,
            "data": {
                "is_heading": 0,
                "text": "Non-pharmacological interventions available."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 104,
            "data": {
                "is_heading": 0,
                "prefix": 11.4,
                "text": "Considerations prior and after treatment has commenced"
            }
        },
        {
            "type": "table",
            "sequence_num": 105,
            "data": {
                "num_rows": 2,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Considerations before prescribing"
                    },
                    {
                        "text": "Considerations once treatment started"
                    },
                    {
                        "text": "Patient vulnerability to specific adverse effects due to existing co- morbidities Contraindications Patient preference Patients' occupation / lifestyle factors Patients' mental health (e.g. coexisting depression) Possible drug interactions Patients' renal / hepatic function"
                    },
                    {
                        "text": "If stopping or switching to a different drug regime, existing drug will need to be tapered / withdrawn slowly according to drug and dosage. When introducing a new drug consider overlapping of old treatment to avoid worsening in pain control. Ask the patient to keep a pain diary. Perform early review of dosage titration, tolerability, adverse effects to"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 106,
            "data": {
                "num_rows": 1,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Are the drugs licensed specifically for certain types of neuropathic pain? Costings of drug therapies Explain the importance of titration and its process. Provide written information where possible. In general, start with monotherapy, but consider combination therapy from early on."
                    },
                    {
                        "text": "assess suitability of chosen treatment. Perform regular clinical reviews to assess and monitor for overall improvement, and need to continue treatment. Ask the patient if there has been any Pain reduction / increase Adverse effects experienced Increase in their daily activities Change in mood Change in sleep pattern"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 107,
            "data": {
                "is_heading": 1,
                "prefix": 12.0,
                "text": "When to refer to the specialist pain service"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 108,
            "data": {
                "is_heading": 0,
                "prefix": 12.1,
                "text": "Consider referring the patient to Specialist Pain Service at any stage, including initial presentation, and at regular clinical reviews if:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 109,
            "data": {
                "is_heading": 0,
                "text": "Pain is severe"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 110,
            "data": {
                "is_heading": 0,
                "text": "Pain significantly limits their daily activities"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 111,
            "data": {
                "is_heading": 0,
                "text": "Patients underlying health has deteriorated"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 112,
            "data": {
                "is_heading": 0,
                "prefix": 12.2,
                "text": "Referral to a Specialist Pain Service does not mean an exit from non-specialist   care by the prescriber but should be viewed as the start to a collaborative   ongoing approach to the management of the patient's neuropathic pain."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 113,
            "data": {
                "is_heading": 0,
                "prefix": 12.3,
                "text": "Continue existing treatment when neuropathic pain is controlled. It will return if   treatment is discontinued."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 114,
            "data": {
                "is_heading": 0,
                "prefix": 12.4,
                "text": "Do not start strong opioids until the patient has been seen and assessed by the   Specialist Pain Service, and that it is felt to be appropriate for the individual."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 115,
            "data": {
                "is_heading": 1,
                "prefix": 13.0,
                "text": "Summary of drug groups"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 116,
            "data": {
                "is_heading": 0,
                "text": "(Refer to appendix 5)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 117,
            "data": {
                "is_heading": 0,
                "prefix": 13.1,
                "text": "Antidepressants: tricyclic antidepressants (TCA's)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 118,
            "data": {
                "is_heading": 0,
                "prefix": 13.2,
                "text": "Antidepressants: selective serotonin reuptake inhibitors (SSRI's)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 119,
            "data": {
                "is_heading": 0,
                "prefix": 13.3,
                "text": "Antidepressants: serotonin-norepinephrine reuptake inhibitors (SNRI's)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 120,
            "data": {
                "is_heading": 0,
                "prefix": 13.4,
                "text": "Anti-epileptics (anticonvulsants)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 121,
            "data": {
                "is_heading": 0,
                "prefix": 13.5,
                "text": "Opioid analgesics."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 122,
            "data": {
                "is_heading": 0,
                "prefix": 13.6,
                "text": "Topical analgesics."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 123,
            "data": {
                "is_heading": 1,
                "prefix": 14.0,
                "text": "Algorithm for pharmacological neuropathic pain care guidelines"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 124,
            "data": {
                "is_heading": 1,
                "prefix": 14.1,
                "text": "It is to be used in conjunction with responsibilities and making a"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 125,
            "data": {
                "is_heading": 1,
                "text": "pharmacological plan section. (Refer to appendix 6)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 126,
            "data": {
                "is_heading": 0,
                "prefix": 14.2,
                "text": "For additional information and advice please refer to Drugs Table for individual"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 127,
            "data": {
                "is_heading": 1,
                "text": "drugs. (Refer to appendix 7)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 128,
            "data": {
                "is_heading": 1,
                "prefix": 15.0,
                "text": "Infection control"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 129,
            "data": {
                "is_heading": 0,
                "prefix": 15.1,
                "text": "All staff should follow Trust guidelines on infection prevention ensuring that they effectively \u2018decontaminate their hands' before and after each procedure."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 130,
            "data": {
                "is_heading": 0,
                "prefix": 15.2,
                "text": "All staff should ensure that they follow Trust guidelines on infection prevention using Aseptic Non-Touch Technique (ANTT) when carrying out procedures."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 131,
            "data": {
                "is_heading": 1,
                "prefix": 16.0,
                "text": "Non-compliance with this policy"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 132,
            "data": {
                "is_heading": 0,
                "prefix": 16.1,
                "text": "Failure to provide regular assessment and effective pain management is a breach of patient rights, and has clinical and non-clinical repercussions:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 133,
            "data": {
                "is_heading": 0,
                "text": "Patient satisfaction and well-being is compromised;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 134,
            "data": {
                "is_heading": 0,
                "text": "Accountability and professional responsibility is breached;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 135,
            "data": {
                "is_heading": 0,
                "text": "Clinical risk is increased, due to multi-systemic influence of pain;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 136,
            "data": {
                "is_heading": 0,
                "text": "Delayed discharge from hospital decreases Trust efficiency and increases risk of hospital-inquired infection."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 137,
            "data": {
                "is_heading": 0,
                "prefix": 16.2,
                "text": "A risk event form should be completed and submitted to the Risk Management department for non-compliance with this guideline."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 138,
            "data": {
                "is_heading": 1,
                "prefix": 17.0,
                "text": "Staff and training"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 139,
            "data": {
                "is_heading": 0,
                "prefix": 17.1,
                "text": "Medical staff are expected to understand the need for the assessment of Neuropathic pain and the clinical importance of treating this type of pain promptly and safely."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 140,
            "data": {
                "is_heading": 0,
                "prefix": 17.2,
                "text": "Training and education is provided by the IPMS, both formally and informally for all clinical staff. The IPMS is available for advice and consultation via the pager system, and through the Lorenzo referral system."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 141,
            "data": {
                "is_heading": 0,
                "prefix": 17.3,
                "text": "Medical staff will be informed of revised guidelines via senior medical staff within the IPMS at audit meetings and twice yearly teaching sessions for all FY1 and FY2 doctors."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 142,
            "data": {
                "is_heading": 0,
                "prefix": 17.4,
                "text": "Corporate services will ensure that the guideline is uploaded to the intranet and the website and notified to staff via the intranet."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 143,
            "data": {
                "is_heading": 1,
                "prefix": 18.0,
                "text": "Audit and monitoring"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 144,
            "data": {
                "is_heading": 0,
                "prefix": 18.1,
                "text": "With the introduction of this new guideline the pharmacy department will be made aware and informed of the policy through structured teaching sessions."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 145,
            "data": {
                "is_heading": 0,
                "prefix": 18.2,
                "text": "At a ward level pharmacy will monitor adherence to the policy and will inform the prescribers and the IPMS of any deviation from the neuropathic guideline."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 146,
            "data": {
                "is_heading": 0,
                "prefix": 18.3,
                "text": "Yearly retrospective examination and audit of patients notes who have been treated for Neuropathic pain. Names of patients who have been seen by the IPMS with neuropathic pain will be collated by the service. 10 of these patients will be randomly selected. Of these 10, their medical records will be sourced and examined. The drug sequencing, ie, what the patient has been started on and dosages, trial periods, and effects; positive and negative will be examined. Any variation from the guideline will need close scrutiny, and feedback will be given to the medical team / prescribing doctor."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 147,
            "data": {
                "is_heading": 0,
                "prefix": 18.4,
                "text": "Where a patient's notes have demonstrated that the appropriate action has not been taken a datix is to be completed. This will address any further training needs for staff that requires updating."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 148,
            "data": {
                "is_heading": 1,
                "prefix": 19.0,
                "text": "Approval and implementation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 149,
            "data": {
                "is_heading": 0,
                "prefix": 19.1,
                "text": "All policies, procedures and guidelines will be approved by the Pain Service Group which is the specialist group with the authority to approve local guidelines. These will then be forwarded to the Document control team for submission and ratification by the Joint Document Management Group."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 150,
            "data": {
                "is_heading": 0,
                "prefix": 19.2,
                "text": "It is the author's responsibility to inform the Pain Service Group of the approved policy documents when they are uploaded to the Trust's Intranets."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 151,
            "data": {
                "is_heading": 0,
                "prefix": 20.1,
                "text": "The Trust is committed to the provision of a service that is fair, accessible and meets the needs of all individuals."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 152,
            "data": {
                "is_heading": 0,
                "text": "(Refer to appendix 8)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 153,
            "data": {
                "is_heading": 0,
                "text": "9.Bennett MI, Attal N, Backonja MM, Baron R, Bouhassira D, Freynhagen R, et al. Using screening tools to identify neuropathic pain (topical review). Pain 2007;127:199-203."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 154,
            "data": {
                "is_heading": 0,
                "text": "10. Jensen T.S.The new grading system of neuropathic pain European Journal of Neurology, September 2010, vol./is. 17/(6), 1351-5101 (September 2010) 11.Gilron I, Max MB. Combination pharmacotherapy for neuropathic pain: current evidence and future directions. Expert Rev Neurother2005;5:823-30."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 155,
            "data": {
                "is_heading": 1,
                "prefix": 22.0,
                "text": "Further Information"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 156,
            "data": {
                "is_heading": 1,
                "text": "Additional educational resources"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 157,
            "data": {
                "is_heading": 0,
                "text": "Special Interest Group on Neuropathic Pain of the IASP (NeuPSIG) www.neupsig.org"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 158,
            "data": {
                "is_heading": 0,
                "text": "Neuropathic Pain Network (NPN) www.neuropathicpainnetwork.org/english/coalition/index.asp"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 159,
            "data": {
                "is_heading": 0,
                "text": "International Association for the Study of Pain (IASP) www.iasp-pain.org"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 160,
            "data": {
                "is_heading": 0,
                "text": "Oxford Pain Internet Site (Bandolier) www.medicine.ox.ac.uk/bandolier/booth/painpag/#Chronic"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 161,
            "data": {
                "is_heading": 1,
                "text": "British Pain Society www.britishpainsociety.org Further help and information"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 162,
            "data": {
                "is_heading": 0,
                "text": "Neuropathy Trust  www.neurocentre.com"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 163,
            "data": {
                "is_heading": 0,
                "text": "Action On Pain  www.action-on-pain.co.uk Pain Relief Foundation www.painrelieffoundation.org.uk Pain Concern  www.painconcern.org.uk Chronic Pain Policy Coalition www.paincoalition.org.uk"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 164,
            "data": {
                "is_heading": 1,
                "prefix": 96.0,
                "text": "Appendix 1: Licensed indications for recommended pharmacological treatments for neuropathic pain (March 2010) NICE guidelines"
            }
        },
        {
            "type": "table",
            "sequence_num": 165,
            "data": {
                "num_rows": 7,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Drug"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Amitriptyline / Nortriptyline"
                    },
                    {
                        "text": "Not licensed for neuropathic pain"
                    },
                    {
                        "text": "Duloxetine"
                    },
                    {
                        "text": "Licensed for painful diabetic neuropathy"
                    },
                    {
                        "text": "Lidocaine (topical)"
                    },
                    {
                        "text": "Licensed for post-herpetic neuralgia"
                    },
                    {
                        "text": "Pregabalin (Lyrica)"
                    },
                    {
                        "text": "Licensed for central and peripheral neuropathic pain"
                    },
                    {
                        "text": "Tramadol"
                    },
                    {
                        "text": "Licensed for moderate to severe pain"
                    },
                    {
                        "text": "Gabapentin"
                    },
                    {
                        "text": "Licensed for neuropathic pain"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 166,
            "data": {
                "is_heading": 1,
                "text": "Appendix 2: Examples of neuropathic pain syndromes"
            }
        },
        {
            "type": "table",
            "sequence_num": 167,
            "data": {
                "num_rows": 7,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Peripheral nervous system"
                    },
                    {
                        "text": "Central Nervous system"
                    },
                    {
                        "text": "Focal and multifocal lesions Cranial neuralgias Trigeminal neuralgia Glossopharyngeal neuralgia Diabetic mononeuropathy Nerve entrapment syndromes Plexopathy from malignancy or radiation Phantom limb pain Post-traumatic neuralgia"
                    },
                    {
                        "text": "Central nervous system lesions Prolapsed disc Stroke (brain / spinal infarction) Multiple Sclerosis Parkinson's disease Surgical lesions Spinal root/dorsal root ganglion Prolapsed disc Root avulsion"
                    },
                    {
                        "text": "Nerve root compression"
                    },
                    {
                        "text": "Trigeminal neuralgia"
                    },
                    {
                        "text": "Post-thoracotomy Scar pain Ischaemic neuropathy Generalised polyneuropathies Metabolic / Nutritional Diabetes mellitus Amyloid Pellagra Hypothyroidism Beriberi Toxic Alcohol"
                    },
                    {
                        "text": "Postherpetic neuralgia (herpes simplex or varicella zoster) Tumour Arachnoiditis Surgical rhizotomy Spinal cord Trauma Multiple sclerosis Vascular: infarction, haemorrhage, arteriovenous malformations HIV and syphilis Syringomyelia and intrinsic tumours Neural tube defect Vitamin B12 deficiency Anterolateral cordotomy."
                    },
                    {
                        "text": "Platinum Taxane based chemotherapy"
                    },
                    {
                        "text": "Brainstem"
                    },
                    {
                        "text": "Isoniazid Antiretroviral drugs Infective / autoimmune HIV Guillain-Barre Syndrome Neuroborreliosis"
                    },
                    {
                        "text": "Lateral medullary syndrome Multiple sclerosis Tumours Tuberculoma Syrinx"
                    },
                    {
                        "text": "Chronic inflammatory demylinating polyneuropathy Heriditary Fabry's Disease Malignancy Carcinomatosis Myeloma Idiopathic small fibre neuropathy"
                    },
                    {
                        "text": "Thalamus Infarction Tumours Haemorrhage Surgical lesions."
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 168,
            "data": {
                "num_rows": 2,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": ""
                    },
                    {
                        "text": "Subcortical and cortical Infarction Trauma Arteriovenous malformation Tumour."
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Complex neuropathic disorders Complex regional pain syndrome I and ll"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 169,
            "data": {
                "is_heading": 1,
                "text": "Appendix 3: DN-4 Neuropathic pain questionnaire"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 170,
            "data": {
                "is_heading": 1,
                "text": "DN4 diagnostic tool (Bouhassira et al 2005)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 171,
            "data": {
                "is_heading": 0,
                "text": "If the answer is yes to 4 or more items, neuropathic mechanisms are likely to be contributing to pain. Please complete this questionnaire by ticking one answer for each item in the 4 questions below:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 172,
            "data": {
                "is_heading": 1,
                "text": "INTERVIEW OF THE PATIENT"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 173,
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "Question : Does the pain have one or more of the following characteristics?"
            }
        },
        {
            "type": "table",
            "sequence_num": 174,
            "data": {
                "num_rows": 4,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Sensation"
                    },
                    {
                        "text": "YES"
                    },
                    {
                        "text": "NO"
                    },
                    {
                        "text": "Burning"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Painful cold"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Electric Shocks"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 175,
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "Question : Is the pain associated with one or more of the following symptoms in the same area?"
            }
        },
        {
            "type": "table",
            "sequence_num": 176,
            "data": {
                "num_rows": 5,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Sensation"
                    },
                    {
                        "text": "YES"
                    },
                    {
                        "text": "NO"
                    },
                    {
                        "text": "Tingling"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Pins and needles"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Numbness"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Itching"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 177,
            "data": {
                "is_heading": 1,
                "text": "EXAMINATION OF THE PATIENT"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 178,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Question : Is the pain located in an area where the physical examination may reveal one or more of the following characteristics?"
            }
        },
        {
            "type": "table",
            "sequence_num": 179,
            "data": {
                "num_rows": 3,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Sensation"
                    },
                    {
                        "text": "YES"
                    },
                    {
                        "text": "NO"
                    },
                    {
                        "text": "1.Hypoesthesia to touch"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "2.Hypoesthesia to prick"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 180,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Question : In the painful area, can the pain be caused or increased by:"
            }
        },
        {
            "type": "table",
            "sequence_num": 181,
            "data": {
                "num_rows": 2,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Sensation"
                    },
                    {
                        "text": "YES"
                    },
                    {
                        "text": "NO"
                    },
                    {
                        "text": "Brushing"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 182,
            "data": {
                "is_heading": 1,
                "text": "Appendix 4:  Glossary of pain terminology"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 183,
            "data": {
                "is_heading": 1,
                "text": "Symptom  Definition"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 184,
            "data": {
                "is_heading": 0,
                "text": "Dysaesthesia  Unpleasant abnormal sensations, not necessarily painful Paraesthesia  An abnormal sensation, but not unpleasant or painful Anaesthesia  Lack of sensation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 185,
            "data": {
                "is_heading": 0,
                "text": "Allodynia  Pain from stimulus that would not normally produce pain Hyperalgesia  An increases response to a stimulus which is normally painful Hyperaesthesia  Increased sensitivity to stimulation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 186,
            "data": {
                "is_heading": 0,
                "text": "Hyperpathia  Abnormal pain response to stimuli applied to an area of"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 187,
            "data": {
                "is_heading": 0,
                "text": "decreased sensitivity"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 188,
            "data": {
                "is_heading": 0,
                "text": "Hypoaesthesia  Decreased sensitivity to stimulation Hypoalgesia  Decreased sensitivity to painful stimuli"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 189,
            "data": {
                "is_heading": 1,
                "text": "Appendix 5: Pharmacological treatments considered for the clinical guideline on neuropathic pain"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 190,
            "data": {
                "is_heading": 1,
                "text": "When there is supporting evidence for analgesic effect"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 191,
            "data": {
                "is_heading": 0,
                "text": "When there is supporting evidence for analgesic effect but mainly nociceptive in origin When supporting evidence is weak but clinical judgement used to warrant prescription"
            }
        },
        {
            "type": "table",
            "sequence_num": 192,
            "data": {
                "num_rows": 17,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Drug class: subclass"
                    },
                    {
                        "text": "Drug"
                    },
                    {
                        "text": "Antidepressants:tricyclic antidepressants (TCA's)"
                    },
                    {
                        "text": "Amitriptyline"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Nortriptyline"
                    },
                    {
                        "text": "Antidepressants:selective serotonin reuptake inhibitors(SSRI's)"
                    },
                    {
                        "text": "None identified"
                    },
                    {
                        "text": "Antidepressants:serotonin-norepinephrine reuptake inhibitors (SNRI's)"
                    },
                    {
                        "text": "Duloxetine"
                    },
                    {
                        "text": "Anti-epileptics (anticonvulsants)"
                    },
                    {
                        "text": "Gabapentin"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Pregabalin"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Carbamazepine"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Oxcarbazepine"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Topiramate"
                    },
                    {
                        "text": "Opioid analgesics"
                    },
                    {
                        "text": "Buprenorphine"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Fentanyl"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Morphine"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Oxycodone"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Tramadol"
                    },
                    {
                        "text": "Topical treatments"
                    },
                    {
                        "text": "Topical Capsaicin"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Topical Lidocaine"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 193,
            "data": {
                "is_heading": 1,
                "text": "Appendix 6: Algorithm for pharmacological neuropathic pain care"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 194,
            "data": {
                "is_heading": 1,
                "text": "guidelines"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 195,
            "data": {
                "is_heading": 0,
                "text": "(next page)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 196,
            "data": {
                "is_heading": 0,
                "text": "Neuropathic pain \u2013 general guidelines and essential information/11063/4.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 197,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 198,
            "data": {
                "is_heading": 1,
                "text": "Mid Essex Hospital Trust Pharmacological Neuropathic Pain Care Guidelines"
            }
        },
        {
            "type": "image",
            "sequence_num": 199,
            "data": {
                "url": "11063 Neuropathic pain 4.0.011.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 200,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 201,
            "data": {
                "is_heading": 1,
                "text": "Referral  to  the  IPMS  can  be ma de  at  any  stage,  including initial  presentation  and  at regular review if"
            }
        },
        {
            "type": "image",
            "sequence_num": 202,
            "data": {
                "url": "11063 Neuropathic pain 4.0.012.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 203,
            "data": {
                "is_heading": 1,
                "text": "patient has severe pain"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 204,
            "data": {
                "is_heading": 0,
                "text": "pain significantly limiting daily activities"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 205,
            "data": {
                "is_heading": 0,
                "text": "their underlying health condition has deteriorated"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 206,
            "data": {
                "is_heading": 1,
                "text": "Neuropathic Pain"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 207,
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "st line Offer a choice of Amitriptyline, Duloxetine, Gabapentin as initial treatment for neuropathic pain"
            }
        },
        {
            "type": "image",
            "sequence_num": 208,
            "data": {
                "url": "11063 Neuropathic pain 4.0.013.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 209,
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "nd line If the initial treatment is not effective or is not tolerated, offer one of the remaining drugs, or an alternative initiated by the Pain team"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 210,
            "data": {
                "is_heading": 1,
                "text": "Opioids: **Morphine, **Tapentadol"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 211,
            "data": {
                "is_heading": 1,
                "text": "Consider opiates only if acute rescue therapy is needed **To be prescribed only by the IPMS"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 212,
            "data": {
                "is_heading": 1,
                "text": "Drug dosages"
            }
        },
        {
            "type": "table",
            "sequence_num": 213,
            "data": {
                "num_rows": 3,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Specific conditions"
                    },
                    {
                        "text": "Trigeminal Neuralgia and Atypical facial pain 1st line anti-neuropathic to be used is Carbamazepine. If ineffective seek Specialist Pain advice."
                    },
                    {
                        "text": "Complex Regional Pain Syndrome (CRPS) if suspected urgent referral to the IPMS to be made"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 214,
            "data": {
                "is_heading": 0,
                "text": "Start at a low dose, as indicated in the table"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 215,
            "data": {
                "is_heading": 0,
                "text": "Titrate upwards to maximum dose or the patients' maximum tolerated dose ( no higher than maximum dose indicated in table)"
            }
        },
        {
            "type": "table",
            "sequence_num": 216,
            "data": {
                "num_rows": 4,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Drug"
                    },
                    {
                        "text": "Starting dose"
                    },
                    {
                        "text": "Maximum dose"
                    },
                    {
                        "text": "Amitriptyline"
                    },
                    {
                        "text": "10mgs/day at night"
                    },
                    {
                        "text": "75mgs/day at night"
                    },
                    {
                        "text": "Duloxetine"
                    },
                    {
                        "text": "30mgs/day"
                    },
                    {
                        "text": "120mgs/day divided doses"
                    },
                    {
                        "text": "Gabapentin"
                    },
                    {
                        "text": "See BNF titration"
                    },
                    {
                        "text": "1800mgs/day divided doses"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 217,
            "data": {
                "is_heading": 1,
                "text": "Combination Therapy"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 218,
            "data": {
                "is_heading": 0,
                "text": "If  some  therapeutic  effect  seen  with  monothepary  but  unable  to  titrate upwards to maximum dose or the patients' maximum tolerated dose without side  effect  consider introducing another  drug  from  another  class  of anti- neuropathic. For example Amitriptyline and Gabapentin together."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 219,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 220,
            "data": {
                "is_heading": 1,
                "text": "Appendix 7: Drugs table"
            }
        },
        {
            "type": "table",
            "sequence_num": 221,
            "data": {
                "num_rows": 8,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "DRUG"
                    },
                    {
                        "text": "DOSE & ROUTE"
                    },
                    {
                        "text": "MAXIMUM DAILY DOSE"
                    },
                    {
                        "text": "DOSE TITRATION & TRIAL"
                    },
                    {
                        "text": "SIDE EFFECTS & COMMENTS"
                    },
                    {
                        "text": "Generalised Neuropathic Pain"
                    },
                    {
                        "text": "1st line"
                    },
                    {
                        "text": "Amitriptyline / Nortriptryline"
                    },
                    {
                        "text": "Initially 10mg orally at night"
                    },
                    {
                        "text": "75mgs at night"
                    },
                    {
                        "text": "Duration of adequate trial 3 months."
                    },
                    {
                        "text": "Use Nortriptyline in place of Amitriptyline if sedation is problematic. Side-effects: Dry mouth, sedation, cardiotoxicity, postural hypotension, bladder problems, constipation. Give dose at night to minimise sedation. Unlicensed for neuropathic pain."
                    },
                    {
                        "text": "Duloxetine"
                    },
                    {
                        "text": "Initially 30mgs/day orally"
                    },
                    {
                        "text": "Increase to 60mgs/day. Can be increased further to 120mgs/day in divided doses"
                    },
                    {
                        "text": "Duration of adequate trail 2 months."
                    },
                    {
                        "text": "Licensed for diabetic neuropathy. However, Amitriptyline can be used if clinically appropriate. Side effects include; drowsiness, constipation, dry mouth, insomnia, and nausea."
                    },
                    {
                        "text": "Gabapentin"
                    },
                    {
                        "text": "300mgs od day 1, 300mgs bd day 2, 300mgs tds day 3 Smaller starting doses in elderly, renally impaired. See BNF."
                    },
                    {
                        "text": "1.8g daily in divided doses."
                    },
                    {
                        "text": "See dose and route. Duration of adequate trial 3 months."
                    },
                    {
                        "text": "Side effects; dry mouth, dizziness and cognitive impairment. Licensed for the treatment of Neuropathic Pain. Different doses apply to renally impaired / dialysis patients."
                    },
                    {
                        "text": "2nd line \u2013 To be initiated by the Specialist Pain Service only"
                    },
                    {
                        "text": "Pregabalin"
                    },
                    {
                        "text": "Initially 25mgs bd orally"
                    },
                    {
                        "text": "Increased by 25mgs bd every 7 days. Maximum dose is 600mgs/day in divided doses."
                    },
                    {
                        "text": "Continue use ONLY if beneficial pain relief seen following a 1-2 month trial."
                    },
                    {
                        "text": "Pregabalin has NOT been proven to be any more or less effective than Gabapentin. Consider if side effects related to Gabapentin experienced."
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 222,
            "data": {
                "num_rows": 4,
                "num_cols": 4,
                "table_items": [
                    {
                        "text": "Localised Neuropathic Pain \u2013 this may include Post-herpetic neuralgia, diabetic neuropathy, scar pain To be initiated by the Specialist Pain Service only"
                    },
                    {
                        "text": "DRUG"
                    },
                    {
                        "text": "DOSE & ROUTE"
                    },
                    {
                        "text": "MAXIMUM DAILY DOSE"
                    },
                    {
                        "text": "DOSE TITRATION & TRIAL"
                    },
                    {
                        "text": "SIDE EFFECTS & COMMENTS"
                    },
                    {
                        "text": "5% Lidocaine Plaster (Versatis)"
                    },
                    {
                        "text": "1-2 plasters applied to the painful area. They are to be kept on for 12 hours with a 12 hour period of no plaster. They are to be re-applied after this in the same way, ie, 12 hours on, 12 hours off each day"
                    },
                    {
                        "text": "Some pain relief may be experienced on first application. Full effect may take 2-4 weeks."
                    },
                    {
                        "text": "1 month trial period."
                    },
                    {
                        "text": "For localised Neuropathic pain only. If effective repeat prescription needs to be carried out by the patients GP. Not to be used on broken skin."
                    },
                    {
                        "text": "Capsaicin Cream"
                    },
                    {
                        "text": "0.075% Capsaicin (Axsain)"
                    },
                    {
                        "text": "Apply sparingly up to every 4 hours. Not to be used on broken skin, unhealed herpetic lesions. Use gloves when applying or wash hands immediately post application."
                    },
                    {
                        "text": "Treatment has to continue for 6 weeks for permanent effect."
                    },
                    {
                        "text": "For use in Painful diabetic neuropathy and post herpetic neuralgia. Can be useful for small areas of allodynia. Licensed for use in post herpetic neuralgia. Transient burning sensation will occur on application. This is normal and is part of its effect. Persevere for effect."
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 223,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 224,
            "data": {
                "is_heading": 0,
                "text": "Neuropathic pain \u2013 general guidelines and essential information/11063/4.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 225,
            "data": {
                "is_heading": 1,
                "text": "Appendix 8: Preliminary equality analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 226,
            "data": {
                "is_heading": 1,
                "text": "This assessment relates to: Neuropathic pain/11063 (please tick all that apply)"
            }
        },
        {
            "type": "table",
            "sequence_num": 227,
            "data": {
                "num_rows": 3,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "\u2610 A change in a service to patients"
                    },
                    {
                        "text": "\u2612 A change to an existing document"
                    },
                    {
                        "text": "\u2610 A change to the way staff work"
                    },
                    {
                        "text": "\u2610 A new document"
                    },
                    {
                        "text": "\u2610 Something else (please give details)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 228,
            "data": {
                "num_rows": 7,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Questions"
                    },
                    {
                        "text": "Answers"
                    },
                    {
                        "text": "1."
                    },
                    {
                        "text": "What are you proposing to change?"
                    },
                    {
                        "text": "Full review and transfer to MSE template"
                    },
                    {
                        "text": "2."
                    },
                    {
                        "text": "Why are you making this change? (What will the change achieve?)"
                    },
                    {
                        "text": "3 yearly review"
                    },
                    {
                        "text": "3."
                    },
                    {
                        "text": "Who benefits from this change and how?"
                    },
                    {
                        "text": "Patients and Clinicians"
                    },
                    {
                        "text": "4."
                    },
                    {
                        "text": "Is anyone likely to suffer any negative impact as a result of this change? If no, please record reasons here and sign and date this assessment. If yes, please complete a full EIA."
                    },
                    {
                        "text": "No"
                    },
                    {
                        "text": "5."
                    },
                    {
                        "text": "a) Will you be undertaking any consultation as part of this change?"
                    },
                    {
                        "text": "Yes"
                    },
                    {
                        "text": "b) If so, with whom?"
                    },
                    {
                        "text": "Please refer to pages 1 and 2"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 229,
            "data": {
                "num_rows": 2,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Preliminary analysis completed by:"
                    },
                    {
                        "text": "Name"
                    },
                    {
                        "text": "Claudine Riordan"
                    },
                    {
                        "text": "Job Title"
                    },
                    {
                        "text": "Pain CNS"
                    },
                    {
                        "text": "19 March 2021"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 230,
            "data": {
                "is_heading": 1,
                "prefix": 27.0,
                "text": "Page  of"
            }
        }
    ]
}